Immunogenicity and effect of a virosomal influenza vaccine on viral replication and T-cell activation in HIV-infected children receiving highly active antiretroviral therapy

Elisabetta Tanzi, Susanna Esposito, Jelena Bojanin, Antonella Amendola, Daria Trabattoni, Elena Pariani, Raffaella Pinzani, Alessandro Zanetti, Nicola Principi

Research output: Contribution to journalArticle

Abstract

In order to evaluate the immunogenicity and the effect of a virosomal influenza vaccine on viral replication and T-cell activation in HIV-infected children receiving highly active antiretroviral therapy (HAART), 29 children infected with HIV-1 vertically (19 primed with a previous influenza vaccination and 10 who were not been immunized against influenza) were immunized with an intramuscular virosome-adjuvanted influenza vaccine. According to the European Agency for Evaluation of Medical Products (EMEA) criteria, the immunogenicity of the vaccine was adequate against all three influenza strains (A H1N1, A H3N2, and B) in the primed children, and against A H1N1 and AH3N2 in the unprimed children. After in vitro stimulation with vaccine antigens, the IFN-γ levels in the peripheral blood mononuclear cells cultures increased significantly from a baseline level of 103.0±229.8 pg/ml to a 30-day level of 390.7±606.3 pg/ml (P <0.05), with concentrations significantly higher (P <0.05) in the primed children than in the unprimed children. No increase in plasma HIV-1 RNA or HIV-1 proviral DNA was observed in either subgroup, and the immunophenotype analyses demonstrated that the CD4 + cell counts and percentages, the CD4/CD8 ratio and activated lymphocytes remained stable in either group from baseline to 1 month after each vaccine dose. This study showed that the virosomal influenza vaccine does seem to be immunogenic in the majority of HIV-infected children receiving HAART and does not induce viral replication or T-cell activation. Given the possible influenza-related complications in children infected with HIV, these results support the use of this influenza vaccine in such patients.

Original languageEnglish
Pages (from-to)440-445
Number of pages6
JournalJournal of Medical Virology
Volume78
Issue number4
DOIs
Publication statusPublished - Apr 2006

Fingerprint

Influenza Vaccines
Highly Active Antiretroviral Therapy
HIV
T-Lymphocytes
Human Influenza
HIV-1
Virosomes
Vaccines
CD4-CD8 Ratio
CD4 Lymphocyte Count
Blood Cells
Vaccination
Cell Culture Techniques
Lymphocytes
RNA
Antigens
DNA

Keywords

  • Children
  • HIV
  • Immunogenicity
  • Influenza vaccine
  • T-cell activation
  • Viral replication

ASJC Scopus subject areas

  • Virology

Cite this

Immunogenicity and effect of a virosomal influenza vaccine on viral replication and T-cell activation in HIV-infected children receiving highly active antiretroviral therapy. / Tanzi, Elisabetta; Esposito, Susanna; Bojanin, Jelena; Amendola, Antonella; Trabattoni, Daria; Pariani, Elena; Pinzani, Raffaella; Zanetti, Alessandro; Principi, Nicola.

In: Journal of Medical Virology, Vol. 78, No. 4, 04.2006, p. 440-445.

Research output: Contribution to journalArticle

Tanzi, Elisabetta ; Esposito, Susanna ; Bojanin, Jelena ; Amendola, Antonella ; Trabattoni, Daria ; Pariani, Elena ; Pinzani, Raffaella ; Zanetti, Alessandro ; Principi, Nicola. / Immunogenicity and effect of a virosomal influenza vaccine on viral replication and T-cell activation in HIV-infected children receiving highly active antiretroviral therapy. In: Journal of Medical Virology. 2006 ; Vol. 78, No. 4. pp. 440-445.
@article{5f855e2e85664a28abfc320b3b68858e,
title = "Immunogenicity and effect of a virosomal influenza vaccine on viral replication and T-cell activation in HIV-infected children receiving highly active antiretroviral therapy",
abstract = "In order to evaluate the immunogenicity and the effect of a virosomal influenza vaccine on viral replication and T-cell activation in HIV-infected children receiving highly active antiretroviral therapy (HAART), 29 children infected with HIV-1 vertically (19 primed with a previous influenza vaccination and 10 who were not been immunized against influenza) were immunized with an intramuscular virosome-adjuvanted influenza vaccine. According to the European Agency for Evaluation of Medical Products (EMEA) criteria, the immunogenicity of the vaccine was adequate against all three influenza strains (A H1N1, A H3N2, and B) in the primed children, and against A H1N1 and AH3N2 in the unprimed children. After in vitro stimulation with vaccine antigens, the IFN-γ levels in the peripheral blood mononuclear cells cultures increased significantly from a baseline level of 103.0±229.8 pg/ml to a 30-day level of 390.7±606.3 pg/ml (P <0.05), with concentrations significantly higher (P <0.05) in the primed children than in the unprimed children. No increase in plasma HIV-1 RNA or HIV-1 proviral DNA was observed in either subgroup, and the immunophenotype analyses demonstrated that the CD4 + cell counts and percentages, the CD4/CD8 ratio and activated lymphocytes remained stable in either group from baseline to 1 month after each vaccine dose. This study showed that the virosomal influenza vaccine does seem to be immunogenic in the majority of HIV-infected children receiving HAART and does not induce viral replication or T-cell activation. Given the possible influenza-related complications in children infected with HIV, these results support the use of this influenza vaccine in such patients.",
keywords = "Children, HIV, Immunogenicity, Influenza vaccine, T-cell activation, Viral replication",
author = "Elisabetta Tanzi and Susanna Esposito and Jelena Bojanin and Antonella Amendola and Daria Trabattoni and Elena Pariani and Raffaella Pinzani and Alessandro Zanetti and Nicola Principi",
year = "2006",
month = "4",
doi = "10.1002/jmv.20559",
language = "English",
volume = "78",
pages = "440--445",
journal = "Journal of Medical Virology",
issn = "0146-6615",
publisher = "Wiley-Liss Inc.",
number = "4",

}

TY - JOUR

T1 - Immunogenicity and effect of a virosomal influenza vaccine on viral replication and T-cell activation in HIV-infected children receiving highly active antiretroviral therapy

AU - Tanzi, Elisabetta

AU - Esposito, Susanna

AU - Bojanin, Jelena

AU - Amendola, Antonella

AU - Trabattoni, Daria

AU - Pariani, Elena

AU - Pinzani, Raffaella

AU - Zanetti, Alessandro

AU - Principi, Nicola

PY - 2006/4

Y1 - 2006/4

N2 - In order to evaluate the immunogenicity and the effect of a virosomal influenza vaccine on viral replication and T-cell activation in HIV-infected children receiving highly active antiretroviral therapy (HAART), 29 children infected with HIV-1 vertically (19 primed with a previous influenza vaccination and 10 who were not been immunized against influenza) were immunized with an intramuscular virosome-adjuvanted influenza vaccine. According to the European Agency for Evaluation of Medical Products (EMEA) criteria, the immunogenicity of the vaccine was adequate against all three influenza strains (A H1N1, A H3N2, and B) in the primed children, and against A H1N1 and AH3N2 in the unprimed children. After in vitro stimulation with vaccine antigens, the IFN-γ levels in the peripheral blood mononuclear cells cultures increased significantly from a baseline level of 103.0±229.8 pg/ml to a 30-day level of 390.7±606.3 pg/ml (P <0.05), with concentrations significantly higher (P <0.05) in the primed children than in the unprimed children. No increase in plasma HIV-1 RNA or HIV-1 proviral DNA was observed in either subgroup, and the immunophenotype analyses demonstrated that the CD4 + cell counts and percentages, the CD4/CD8 ratio and activated lymphocytes remained stable in either group from baseline to 1 month after each vaccine dose. This study showed that the virosomal influenza vaccine does seem to be immunogenic in the majority of HIV-infected children receiving HAART and does not induce viral replication or T-cell activation. Given the possible influenza-related complications in children infected with HIV, these results support the use of this influenza vaccine in such patients.

AB - In order to evaluate the immunogenicity and the effect of a virosomal influenza vaccine on viral replication and T-cell activation in HIV-infected children receiving highly active antiretroviral therapy (HAART), 29 children infected with HIV-1 vertically (19 primed with a previous influenza vaccination and 10 who were not been immunized against influenza) were immunized with an intramuscular virosome-adjuvanted influenza vaccine. According to the European Agency for Evaluation of Medical Products (EMEA) criteria, the immunogenicity of the vaccine was adequate against all three influenza strains (A H1N1, A H3N2, and B) in the primed children, and against A H1N1 and AH3N2 in the unprimed children. After in vitro stimulation with vaccine antigens, the IFN-γ levels in the peripheral blood mononuclear cells cultures increased significantly from a baseline level of 103.0±229.8 pg/ml to a 30-day level of 390.7±606.3 pg/ml (P <0.05), with concentrations significantly higher (P <0.05) in the primed children than in the unprimed children. No increase in plasma HIV-1 RNA or HIV-1 proviral DNA was observed in either subgroup, and the immunophenotype analyses demonstrated that the CD4 + cell counts and percentages, the CD4/CD8 ratio and activated lymphocytes remained stable in either group from baseline to 1 month after each vaccine dose. This study showed that the virosomal influenza vaccine does seem to be immunogenic in the majority of HIV-infected children receiving HAART and does not induce viral replication or T-cell activation. Given the possible influenza-related complications in children infected with HIV, these results support the use of this influenza vaccine in such patients.

KW - Children

KW - HIV

KW - Immunogenicity

KW - Influenza vaccine

KW - T-cell activation

KW - Viral replication

UR - http://www.scopus.com/inward/record.url?scp=33644772845&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33644772845&partnerID=8YFLogxK

U2 - 10.1002/jmv.20559

DO - 10.1002/jmv.20559

M3 - Article

C2 - 16482542

AN - SCOPUS:33644772845

VL - 78

SP - 440

EP - 445

JO - Journal of Medical Virology

JF - Journal of Medical Virology

SN - 0146-6615

IS - 4

ER -